Full-text resources of CEJSH and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl

PL EN


2018 | 21 | 5 | 81-94

Article title

The importance of “disclosure” in relationships between physicians and pharmaceutical companies

Content

Title variants

Languages of publication

EN

Abstracts

EN
The article raises issues of transparency in relationships between doctors and drug manufacturers. It indicates how important it is as a way for physicians and the pharmaceutical industry to regain public trust. The manuscript will define the concept of disclosure. It will discuss in detail The Physician Payment Sunshine Act from the U.S., which imposes a legal obligation on pharmaceutical companies to disclose their relationships with doctors and university hospitals. The article will also show the diverse regulation of disclosure in different countries of the European Union. The situation in Poland will be also described. In the summary, there will be a discussion about the importance of disclosure for patients and the advantages and disadvantages of such regulations for physicians and drug manufacturers.

Year

Volume

21

Issue

5

Pages

81-94

Physical description

Dates

published
2019-03-22

Contributors

  • Warsaw University of Life Sciences, Faculty of Social Sciences, Department of Sociology
  • Maria Curie Skłodowska University of Lublin, Faculty of Economics

References

  • AdvaMed. (n.d.) The Physician Sunshine Act and you. http://advamed.org/res.download/60
  • Agrawal, S., Brennan, N., & Budetti, P. (2013). The Sunshine Act-effects on physicians. New England Journal of Medicine, 368(22), 2054–2057.
  • American Medical Association. (n.d.). Sunshine Act FAQs. http://www.amaassn.org/ama/pub/advocacy/topics/sunshine-act-and-physician-financialtransparency-reports/sunshine-act-faqs.page?
  • Belluz, J. (2014, September 30). Doctors and hospitals got at least $3.5 billion from industry in just five months. Vox. http://www.vox.com/2014/9/30/6868897/you-can-now-search-for-your-doctors-pharma-payments-online-sunshine-act
  • Campbell, E. C., Gruen, R. L., Mountford, J., Miller, L. G., Cleary, P. D., & Blumenthal, D., (2007). A National Survey of Physician – Industry Relationships. The New England Journal of Medicine, 356, 1742–1750.
  • CBOS [Centre for Public Opinion Research]. (1999). Prestiż zawodów [Prestige of profession]. Warszawa: CBOS.
  • CBOS [Centre for Public Opinion Research]. (2013). Prestiż zawodów [Prestige of profession]. Warszawa: CBOS.
  • CBOS [Centre for Public Opinion Research]. 2016. Społeczne oceny uczciwości i rzetelności zawodowej [Social evaluation of honesty and professional integrity]. Warszawa: CBOS.
  • Centers for Medicare & Medicaid Services. (n.d.) Fact Sheet for Physcians, https://www.cms.gov/Regulations-and-Guidance/Legislation/National-Physician-Payment-Transparency-Program/Downloads/Physician-fact-sheet .pdf
  • Centers for Medicare & Medicaid Services. (n.d.) Open Payments Data Summary. https://openpaymentsdata.cms.gov/summary
  • Ciadini, R. (2003). Wywieranie wpływu na ludzi. Teoria i praktyka. Gdańsk: Gdańskie Wydawnictwo Psychologiczne.
  • The CMS Blog. (2016). CMS Releases Third Year of Open Payments Data. https://blog.cms.gov/2016/06/30/cms-releases-third-year-of-open-payments-data/
  • Dhuri, S. (2013). Comparison of the French sunshine act. (Loi Bertrand Law) and the US Sunshine Act. https://pharmapromotional.wordpress.com/2013/09/30/comparison-of-the-french-sunshine-act-loi-bertrand-law-and-the-us-sunshine-act/
  • Hajnosz, I., & Wróblewski, H. (2007). To jak pan korumpował lekarza. Gazeta Wyborcza, 182, p. 6.
  • Halperin, E. C., Hutchison, P., & Barrier Jr, R. C. (2004). A population-based study of the prevalence and influence of gifts to radiation oncologists from pharmaceutical companies and medical equipment manufacturers. International Journal of Radiation Oncology • Biology • Physics, 59(5), 1477–1483.
  • INFARMA. (2008). Kodeks Dobrych Praktyk Przemysłu Farmaceutycznego [Code of Good Practice of the Pharmaceutical Industry]. http://www.infarma. pl/assets/files/etyka/KodeksDobrych Praktyk_Wyd_2_201014_PL.PDF
  • INFARMA. (2015). Kodeks przejrzystości [Transparency Code], http://www.kodeksprzejrzystosci.pl/assets/files/etyka/Kodeks_Przejrzystosci_wydanie_5.pdf
  • INFARMA. (2015–2017). Raport przejrzystości. http://www.kodeksprzejrzystosci.pl/raporty/
  • INFARMA. (2016). Czym jest Kodeks Przejrzystości. http://www.kodeksprzejrzystosci.pl/kodeks-przejrzysto%C5%9Bci/
  • Kruczkowska, M. (2013). Koncerny farmaceutyczne korumpują Chiny. Jeden się pokajał. Gazeta Wyborcza, 172, 8.
  • Lieb, K., & Scheurich, A. (2014). Contact between doctors and the pharmaceutical industry, their perceptions, and the effects on prescribing habits. PLoS One, 9(10). doi: 10.1371/journal.pone.0110130
  • Lizut, M. (2006). Jak ustawić lekarza. Gazeta Wyborcza, 120, 4.
  • Makowska, M. (2010). Etyczne standardy marketingu farmaceutycznego. Warszawa: CeDeWu.
  • Makowska, M. (2012). Rola śledztw dziennikarskich w kreowaniu etycznych standardów marketingu farmaceutycznego. Prakseologia, 152, 125–144.
  • Makowska, M. (2016). Etyczne wyzwania współpracy studentów medycyny z przemysłem farmaceutycznym. Studium porównawcze sytuacji w USA i Polsce. Warszawa: Wydawnictwo Szkoły Głównej Gospodarstwa Wiejskiego.
  • Markowska, M., & Jasiński, Ł. (2017). Znaczenie „przejrzystości” w relacjach lekarzy z firmami farmaceutycznymi. Annales. Ethics in Economic Life, 20(1), 95–109.
  • McDermott, Will & Emery. (2014). Snapshot of sunshine rules in EU countries for the pharmaceutical industry. http://documents.jdsupra.com/beee41ce-968c-484e-9eca-73d39615efb1.pdf
  • Orlowski, J. P., & Wateska, L. (1992). The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch. Chest, 102(1), 270–273.
  • Pham-Kanter, G., Alexander, G. C., & Nair, K. (2012). Effect of physician payment disclosure laws on prescribing. Archives of Internal Medicine, 172(10), 819–821.
  • PolicyMed. (2016). Open Payments Data Summary. http://www.policymed.com/2016/06/open-pay ments-2015-data-released.html
  • Prozilo Life Sciences. (2015). Ready or Not, Full Speed Ahead for the Global Transparency Movement. https://s3-us-west-2.amazonaws.com/porzio/media/1432/porziols-white-paper_august-2015.pdf
  • Rabij, M., (2014). Lekarz zdalnie sterowany. Newsweek Polska, 2, 32–35.
  • Szymborski, T. (2003). Kasa fundacji zabytków. Rzeczpospolita, 123, A1–A4.
  • Wazana, A. (2000). Physicians and the pharmaceutical industry. Is a gift ever just a gift? Journal of American Medical Association, 283(3), 373–380.
  • Zverejňovanie na základe zákona č. 362/2011 Z. z. o liekoch a zdravotníckych pomôckach. http://www.nczisk.sk/Medicinska-statistika/Zverejnovanie_na_zaklade-zakona_362-2011_liekoch_zdravotnickych_pomockach/Stranky/default.aspx

Document Type

Publication order reference

Identifiers

YADDA identifier

bwmeta1.element.ojs-doi-10_18778_1899-2226_21_5_07
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.